Feld, Jordan J <br/><br/>
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.  [electronic resource] 

 -  Journal of hepatology  Feb 2016 
 - 301-307 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1600-0641 
<br/><br/><label>Standard No.: </label>10.1016/j.jhep.2015.10.005  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Adult<br/>Aged<br/>Anilides--administration & dosage<br/>Antiviral Agents--administration & dosage<br/>Carbamates--administration & dosage<br/>Cyclopropanes<br/>Drug Administration Schedule<br/>Drug Combinations<br/>Drug Resistance, Viral<br/>Drug Therapy, Combination--methods<br/>Female<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--complications<br/>Humans<br/>Lactams, Macrocyclic<br/>Liver Cirrhosis--complications<br/>Macrocyclic Compounds--administration & dosage<br/>Male<br/>Middle Aged<br/>Proline--analogs & derivatives<br/>Ribavirin--administration & dosage<br/>Ritonavir--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Sustained Virologic Response<br/>Treatment Outcome<br/>Uracil--administration & dosage<br/>Valine